newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

  • IGC Pharma reported reaching approximately 70% of planned patient enrollment in its Phase 2 CALMA trial for IGC-AD1 treatment of Alzheimer's agitation.
  • The company is utilizing 23 active sites across 26 locations with a hybrid decentralized model to expand patient access.
  • IGC expects to complete enrollment by mid-2026, a milestone that reduces operational risk & positions the trial for database lock & topline results.
  • Efficacy outcomes in the randomized, double-blind, placebo-controlled study will not be analyzed on an interim basis to maintain trial integrity.
  • CEO Ram Mukunda stated that the enrollment progress reflects improved execution & site productivity while maintaining data quality.
  • IGC-AD1 is an investigational cannabinoid-based therapy being evaluated for safety & efficacy in agitation associated with Alzheimer's disease.
  • The company's pipeline includes TGR-63 for amyloid plaques & early-stage programs targeting neurodegeneration, tau proteins, & metabolic dysfunctions.